State Street Corp Invests $1.34 Million in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)

State Street Corp purchased a new position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 86,559 shares of the company's stock, valued at approximately $1,337,000. State Street Corp owned about 0.36% of Artiva Biotherapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of ARTV. BNP Paribas Financial Markets purchased a new position in shares of Artiva Biotherapeutics in the third quarter worth approximately $42,000. MetLife Investment Management LLC purchased a new position in Artiva Biotherapeutics during the 3rd quarter worth approximately $135,000. Charles Schwab Investment Management Inc. acquired a new stake in Artiva Biotherapeutics during the 3rd quarter valued at $623,000. Acuta Capital Partners LLC purchased a new stake in shares of Artiva Biotherapeutics in the third quarter valued at $680,000. Finally, RTW Investments LP acquired a new stake in shares of Artiva Biotherapeutics in the third quarter worth $2,300,000.

Analyst Ratings Changes

ARTV has been the topic of several recent analyst reports. Needham & Company LLC reissued a "buy" rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a research report on Wednesday, November 13th. HC Wainwright began coverage on Artiva Biotherapeutics in a report on Monday. They issued a "buy" rating and a $20.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $21.00.

Artiva Biotherapeutics Price Performance

NASDAQ ARTV traded up $0.70 on Friday, reaching $10.67. The stock had a trading volume of 56,186 shares, compared to its average volume of 50,443. Artiva Biotherapeutics, Inc. has a 1 year low of $9.68 and a 1 year high of $17.31. The firm has a 50 day simple moving average of $11.37.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.24). On average, equities analysts anticipate that Artiva Biotherapeutics, Inc. will post -4.68 EPS for the current year.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.